Autologous transplantation for multiple myeloma

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Harousseau, J L ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; NEW DRUG; PAMIDRONIC ACID; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; ARTICLE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; MULTIPLE MYELOMA; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

EID: 53449084142     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn449     Document Type: Conference Paper

References (55)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
2. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Upfront or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998; 92: 3131-3136.
4. Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: Results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
5. Blade J, Rosinol L, Sureda A et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2005; 106: 3755-3759.
6. Fermand JP, Katsahian S, Divine M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
7. Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of Phase III US Intergroup trial S9321. J Clin Oncol 2006; 24: 929-936.
8. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278-4282.
9. Rajkumar SV, Fonseca R, Lacy MQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267-1272.
10. Koreth J, Cutler CS, Djulbegovic B et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183-196.
11. Gertz M, Lacy MQ, Inwards DJ et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000; 26: 45-50.
12. Attal M, Harousseau JL, Facon T et al. Intergroupe Francophone du Myelome: Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
13. Harousseau JL, Attal M, Moreau P et al. The prognostic impact of complete remission plus very good partial remission in a double-transplantation program for newly diagnosed multiple myeloma. Blood 2006; 108: 877a (abstract).
14. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: What have we learned? Blood 1996; 88: 838-847.
15. Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: Hype or reality.? Bone Marrow Transplant 2005; 35: 215-224.
16. Lahuerta JJ, Martinez-Lopez J, de la Serna J et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
17. Wang M, Delasalle K, Thomas S et al. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 2006; 108: 123a (abstract).
18. Lenhoff S, Hjorth M, Turesson I et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006; 91: 1228-1233.
19. Sonneveld P, van der Holt B, Segeren CM et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term results of the Dutch Cooperative group HOVON 24 trial. Haematologica 2007; 92: 928-935.
20. Pineda-Roman M, Bolejack V, Arzoumian V et al. Complete response in myeloma extends survival, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393-399.
21. van Rhee F, Bolejack V, Hollmig K et al. High serum-free light chain levels and their rapid reduction in response define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
22. van de Velde HJK, Liu X, Chen G et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399-1406.
23. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
24. Durie BG, Harousseau JL, San Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
25. Harousseau JL, Milpied N, Laporte JP et al. Double intensive therapy in high-risk multpile myeloma. Blood 1992; 79: 2827-2833.
26. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem autotransplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
27. Cavo M, Tosi P, Zamagni E et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncal 2007; 25: 2434-2441.
28. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
29. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethsone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
30. Macro M, Divine M, Uzunban Y et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood 2006; 108: 22a (abstract).
31. Lokhorst HM, Schidt-Wolf I, Sonneveld P et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124-127.
32. Morgan GJ, Davies FE, Owen RG et al. Thalidomide combinations improve response rates: Results from the MRC IX study. Blood 2007; 110: 1051a (abstract).
33. Jagannath S, Durie B, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783.
34. Harousseau JL, Attal M, Leleu X et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 2006; 91: 1498-1505.
35. Rosinol L, Oriol A, Mateos MV et al. Phase Ii Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25: 4452-4458.
36. Harousseau JL, Mathiot C, Attal M et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: Updated results of the IFM 2005/01 trial. Blood 2007; 110: 139a (abstract).
37. Oakervee R, Pollat R, Curry N et al. PAD combination (PS341), doxorubicin and dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783.
38. Popat R, Oakervae HE, Curry N et al. Reduced dose PAD for previously untreated patients with multiple myeloma. Blood 2005; 106: 717a (abstract).
39. Wang M, Giralt S, Delasale K et al. Borezomlb in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235-239.
40. Cavo M, Patriarca F, Tacchetti P et al. Bortezomib-thalidomide-dexamethasone vs thalidomide-dexamethasone in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma. Blood 2007; 110: 30a.
41. Lacy MQ, Gertz MA, Dispenzieri A et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179-1184.
42. Rajkumar SV, Jacobus S, Callander N et al. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E403): A trial coordinated by the Eastern Cooperative Oncology Group, Blood 2007; 110: 31a (abstract).
43. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
44. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 15: 3289-3294.
45. Abdelkefi A, Ladeb S, Torjman L et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008; 111: 1805-1810.
46. Spencer A, Prince HM, Roberts A et al. Thalidomide improves survival when used following ASCT. Haematologica 2007; 92: 41-42 (abstract).
47. Singhal S, Melhta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
48. Jagannath S, Richardson PG, Sonneveld P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2.3 trials. Leukemia 2007; 21: 151-157.
49. Sagaster V, Ludwig H, Kaufmann H et al. Bortezomib in relapsed multiple myeloma: Response rates and duration are independent of a chromosome 13q-deletion. Leukemia 2007; 21: 164-168.
50. Bahlis NJ, Mansoor B, Lategan JC et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14): MM016 trial. Blood 2006; 108: 1016a (abstract).
51. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial. Lancet 2006; 367: 825-435.
52. Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by Fish analysis and serum β2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
53. San Miguel JF, Schlag R, Khuageva N et al. MMY-3002: A phase III study comparing bortezomib-melphalan-prednisone with melphalan-prednisone in newly diagnosed multiple myeloma. Blood 2007; 110: 31a (abstract).
54. Barlogie B, Anaissie E, Van Rhee F et al. Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007; 138: 176-185.
55. Ladetto M, Pagliano G, Avonto I et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Blood 2007; 110: 163a (abstract).